FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320492076> ?p ?o ?g. }

• W4320492076 endingPage "380" @default.
• W4320492076 startingPage "380" @default.
• W4320492076 abstract "Background: The prevalence of antimicrobial resistance of Pseudomonas aeruginosa (P. aeruginosa) in solid organ transplant (SOT) recipients is higher than that of the general population. However, the literature supporting this statement is scarce. Identifying patients at risk of carbapenem resistance (CR) is of great importance, as CR strains more often receive inappropriate empiric antibiotic therapy, which is independently associated with mortality in bloodstream infections (BSIs). Methods: We prospectively recorded data from all consecutive BSIs from January 1991 to July 2019 using a routine purpose-designed surveillance database. The following variables were included: age, sex, type of transplant, use of vascular and urinary catheters, presence of neutropenia, period of diagnosis, treatment with steroids, origin of BSI, source of bacteremia, septic shock, ICU admission, mechanical ventilation, previous antibiotic treatment, treatment of bacteremia, and 30-day all-cause mortality. Results: We identified 2057 episodes of P. aeruginosa BSI. Of these, 265 (13%) episodes corresponded to SOT recipients (130 kidney transplants, 105 liver, 9 hearts, and 21 kidney–pancreas). Hematologic malignancy [OR 2.71 (95% CI 1.33–5.51), p = 0.006] and prior carbapenem therapy [OR 2.37 (95% CI 1.46–3.86), p < 0.001] were associated with a higher risk of having a CR P. aeruginosa BSI. Age [OR 1.03 (95% CI 1.02–1.04) p < 0.001], urinary catheter [OR 2.05 (95% CI 0.37–3.06), p < 0.001], shock at onset [OR 6.57 (95% CI 4.54–9.51) p < 0.001], high-risk source [OR 4.96 (95% CI 3.32–7.43) p < 0.001], and bacteremia caused by CR strains [OR 1.53 (95% CI 1.01–2.29) p = 0.036] were associated with increased mortality. Correct empirical therapy was protective [OR 0.52 (95% CI 0.35–0.75) p = 0.001]. Mortality at 30 days was higher in non-SOT patients (21% vs. 13%, p = 0.002). SOT was not associated with a higher risk of having a CR P. aeruginosa BSI or higher mortality. Conclusions: In our cohort of 2057 patients with P. aeruginosa BSIs, hematologic malignancies and previous carbapenem therapy were independently associated with a risk of presenting CR P. aeruginosa BSI. Age, urinary catheter, high-risk source, bacteremia caused by carbapenem-resistant strains, and severity of the infection were independently associated with mortality, whereas correct empirical therapy was a protective factor. An increasing trend in the resistance of P. aeruginosa was found, with >30% of the isolates being resistant to carbapenems in the last period. SOT was not associated with a higher risk of carbapenem-resistant BSIs or higher mortality." @default.
• W4320492076 created "2023-02-14" @default.
• W4320492076 creator A5003310248 @default.
• W4320492076 creator A5011520405 @default.
• W4320492076 creator A5012294382 @default.
• W4320492076 creator A5014122181 @default.
• W4320492076 creator A5017384483 @default.
• W4320492076 creator A5018939474 @default.
• W4320492076 creator A5026597427 @default.
• W4320492076 creator A5031214309 @default.
• W4320492076 creator A5037870324 @default.
• W4320492076 creator A5044869929 @default.
• W4320492076 creator A5057610160 @default.
• W4320492076 creator A5070507509 @default.
• W4320492076 creator A5079863232 @default.
• W4320492076 creator A5081446167 @default.
• W4320492076 creator A5081557315 @default.
• W4320492076 creator A5082894673 @default.
• W4320492076 creator A5083203472 @default.
• W4320492076 creator A5088119944 @default.
• W4320492076 date "2023-02-13" @default.
• W4320492076 modified "2023-10-08" @default.
• W4320492076 title "Pseudomonas aeruginosa Bloodstream Infection, Resistance, and Mortality: Do Solid Organ Transplant Recipients Do Better or Worse?" @default.
• W4320492076 cites W1058319730 @default.
• W4320492076 cites W1970224194 @default.
• W4320492076 cites W2001701005 @default.
• W4320492076 cites W2002773042 @default.
• W4320492076 cites W2027225993 @default.
• W4320492076 cites W2041667108 @default.
• W4320492076 cites W2059728033 @default.
• W4320492076 cites W2103121782 @default.
• W4320492076 cites W2115806935 @default.
• W4320492076 cites W2131948745 @default.
• W4320492076 cites W2142343447 @default.
• W4320492076 cites W2280404143 @default.
• W4320492076 cites W2335669234 @default.
• W4320492076 cites W2336484441 @default.
• W4320492076 cites W2365841456 @default.
• W4320492076 cites W2507780315 @default.
• W4320492076 cites W2613519430 @default.
• W4320492076 cites W2769272184 @default.
• W4320492076 cites W2792337949 @default.
• W4320492076 cites W2981871343 @default.
• W4320492076 cites W2990002543 @default.
• W4320492076 cites W2990210118 @default.
• W4320492076 cites W3025090436 @default.
• W4320492076 cites W3083892815 @default.
• W4320492076 cites W3111675840 @default.
• W4320492076 cites W3114918623 @default.
• W4320492076 cites W3203985083 @default.
• W4320492076 cites W3211877253 @default.
• W4320492076 cites W4220792895 @default.
• W4320492076 cites W4226437178 @default.
• W4320492076 cites W4309655338 @default.
• W4320492076 doi "https://doi.org/10.3390/antibiotics12020380" @default.
• W4320492076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36830291" @default.
• W4320492076 hasPublicationYear "2023" @default.
• W4320492076 type Work @default.
• W4320492076 citedByCount "0" @default.
• W4320492076 crossrefType "journal-article" @default.
• W4320492076 hasAuthorship W4320492076A5003310248 @default.
• W4320492076 hasAuthorship W4320492076A5011520405 @default.
• W4320492076 hasAuthorship W4320492076A5012294382 @default.
• W4320492076 hasAuthorship W4320492076A5014122181 @default.
• W4320492076 hasAuthorship W4320492076A5017384483 @default.
• W4320492076 hasAuthorship W4320492076A5018939474 @default.
• W4320492076 hasAuthorship W4320492076A5026597427 @default.
• W4320492076 hasAuthorship W4320492076A5031214309 @default.
• W4320492076 hasAuthorship W4320492076A5037870324 @default.
• W4320492076 hasAuthorship W4320492076A5044869929 @default.
• W4320492076 hasAuthorship W4320492076A5057610160 @default.
• W4320492076 hasAuthorship W4320492076A5070507509 @default.
• W4320492076 hasAuthorship W4320492076A5079863232 @default.
• W4320492076 hasAuthorship W4320492076A5081446167 @default.
• W4320492076 hasAuthorship W4320492076A5081557315 @default.
• W4320492076 hasAuthorship W4320492076A5082894673 @default.
• W4320492076 hasAuthorship W4320492076A5083203472 @default.
• W4320492076 hasAuthorship W4320492076A5088119944 @default.
• W4320492076 hasBestOaLocation W43204920761 @default.
• W4320492076 hasConcept C126322002 @default.
• W4320492076 hasConcept C177713679 @default.
• W4320492076 hasConcept C2776694085 @default.
• W4320492076 hasConcept C2777063308 @default.
• W4320492076 hasConcept C2777628635 @default.
• W4320492076 hasConcept C2777637488 @default.
• W4320492076 hasConcept C2778384902 @default.
• W4320492076 hasConcept C2779443120 @default.
• W4320492076 hasConcept C2908647359 @default.
• W4320492076 hasConcept C501593827 @default.
• W4320492076 hasConcept C523546767 @default.
• W4320492076 hasConcept C54355233 @default.
• W4320492076 hasConcept C71924100 @default.
• W4320492076 hasConcept C86803240 @default.
• W4320492076 hasConcept C89423630 @default.
• W4320492076 hasConcept C99454951 @default.
• W4320492076 hasConceptScore W4320492076C126322002 @default.
• W4320492076 hasConceptScore W4320492076C177713679 @default.
• W4320492076 hasConceptScore W4320492076C2776694085 @default.

• next